Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis.

Published on Jul 20, 2020in The Lancet Gastroenterology & Hepatology14.789
· DOI :10.1016/S2468-1253(20)30217-X
Priya Oka1
Estimated H-index: 1
(University of Leeds),
Heather Parr1
Estimated H-index: 1
(University of Leeds)
+ 3 AuthorsAlexander C. Ford86
Estimated H-index: 86
(University of Leeds)
Sources
Abstract
Summary Background Irritable bowel syndrome (IBS) is one of the most common functional bowel disorders, but community prevalence appears to vary widely between different countries. This variation might be due to the fact that previous cross-sectional surveys have neither applied uniform diagnostic criteria nor used identical methodology, rather than being due to true global variability. We aimed to determine the global prevalence of IBS. Methods We did a systematic review and meta-analysis of data from all population-based studies using relatively uniform methodology and using only the most recent iterations of the Rome criteria (Rome III and IV). We searched MEDLINE, Embase, and Embase Classic (from Jan 1, 2006, to April 30, 2020) to identify cross-sectional surveys reporting the prevalence of IBS in adults (≥90% of participants aged ≥18 years) according to the Rome III or Rome IV criteria. We also hand-searched a selection of conference proceedings for relevant abstracts published between 2006 and 2019. We extracted prevalence data for all studies, according to the criteria used to define the presence of IBS. We did a meta-analysis to estimate pooled prevalence rates, according to study location and certain other characteristics (eg, sex and IBS subtype). Findings We identified 4143 citations, of which 184 studies appeared relevant. 57 of these studies were eligible, and represented 92 separate adult populations, comprising 423 362 participants. The pooled prevalence of IBS in 53 studies that used the Rome III criteria, from 38 countries and comprising 395 385 participants, was 9·2% (95% CI 7·6–10·8; I2=99·7%). By contrast, pooled IBS prevalence among six studies that used the Rome IV criteria, from 34 countries and comprising 82 476 individuals, was 3·8% (95% CI 3·1–4·5; I2=96·6%). IBS with mixed bowel habit (IBS-M) was the most common subtype with the Rome III criteria, reported by 33·8% (95% CI 27·8–40·0; I2=98·1%) of people fulfilling criteria for IBS (ie, 3·7% [2·6–4·9] of all included participants had IBS-M), but IBS with diarrhoea (IBS-D) was the most common subtype with the Rome IV criteria (reported by 31·5% [95% CI 23·2–40·5; I2=98·1% 61·6%] of people with IBS, corresponding to 1·4% [0·9–1·9] of all included participants having IBS-D). The prevalence of IBS was higher in women than in men (12·0% [95% CI 9·3–15·0] vs 8·6% [6·3–11·2]; odds ratio 1·46 [95% CI 1·33–1·59]). Prevalence varied substantially between individual countries, and this variability persisted even when the same diagnostic criteria were applied and identical methodology was used in studies. Interpretation Even when uniform symptom-based criteria are applied, based on identical methodology, to define the presence of IBS, prevalence varies substantially between countries. Prevalence was substantially lower with the Rome IV criteria, suggesting that these more restrictive criteria might be less suitable than Rome III for population-based epidemiological surveys. Funding None.
📖 Papers frequently viewed together
14 Citations
3 Citations
References80
Newest
#1Ami D. Sperber (BGU: Ben-Gurion University of the Negev)H-Index: 31
#2Shrikant I. Bangdiwala (McMaster University)H-Index: 75
Last. Olafur S. Palsson (UNC: University of North Carolina at Chapel Hill)H-Index: 50
view all 48 authors...
Abstract Background & Aims Although functional gastrointestinal disorders (FGIDs), now called disorders of gut–brain interaction, have major economic effects on healthcare systems and adversely affect quality of life, little is known about their global prevalence and distribution. We investigated the prevalence of and factors associated with 22 FGIDs, in 33 countries on 6 continents. Methods Data were collected via the internet in 24 countries, personal interviews in 7 countries, and both in 2 c...
125 CitationsSource
#1Shawn L. Shah (NewYork–Presbyterian Hospital)H-Index: 10
#2Nigeen H. Janisch (Dartmouth–Hitchcock Medical Center)H-Index: 2
Last. Brian E. Lacy (Mayo Clinic)H-Index: 54
view all 4 authors...
Abstract Background & Aims Irritable bowel syndrome (IBS) is a common chronic functional bowel disorder for which patients take significant risks to ameliorate symptoms. Unfortunately, there is no cure for IBS. We assessed the willingness of patients with IBS to take medication risks and the costs they would pay to improve symptoms. Methods We mailed a survey on medication risk taking to patients with IBS who meet the Rome IV criteria. The survey collected data on patient demographics, symptoms,...
4 CitationsSource
#1Christopher J Black (University of Leeds)H-Index: 13
#2Nicholas E Burr (University of Leeds)H-Index: 14
Last. Alexander C. Ford (University of Leeds)H-Index: 86
view all 3 authors...
: Irritable bowel syndrome (IBS) is a chronic functional bowel disorder affecting 1 in 10 people and associated with poor psychological health, reduced quality of life, and increased health care expenditure.1 The etiology is complex and incompletely understood.2 Approximately one-third of patients have IBS with constipation (IBS-C),1 for which there are licensed therapies available in the United States. We summarized comparative efficacy of these in a recent network meta-analysis of randomized c...
26 CitationsSource
#1Christopher J BlackH-Index: 13
#2Elyse R. ThakurH-Index: 1
Last. Alexander C. FordH-Index: 86
view all 6 authors...
Objectives National guidelines for the management of irritable bowel syndrome (IBS) recommend that psychological therapies should be considered, but their relative efficacy is unknown, because there have been few head-to-head trials. We performed a systematic review and network meta-analysis to try to resolve this uncertainty. Design We searched the medical literature through January 2020 for randomised controlled trials (RCTs) assessing efficacy of psychological therapies for adults with IBS, c...
33 CitationsSource
#1Olafur S. Palsson (UNC: University of North Carolina at Chapel Hill)H-Index: 50
#2William E. Whitehead (UNC: University of North Carolina at Chapel Hill)H-Index: 102
Last. Magnus Simrén (UNC: University of North Carolina at Chapel Hill)H-Index: 78
view all 5 authors...
Abstract Background & Aims Little is known about the population prevalence or demographic distributions of Rome IV functional bowel disorders (FBDs) or their effects on quality of life. We examined these in a multi-national survey. Methods We analyzed data from a population-based survey of adults in the United States, Canada, and United Kingdom (5931 valid responders; 49.2% female; mean age, 47.4 years; range, 18–92 years). The survey included the Rome IV Diagnostic Questionnaire, Rome III irrit...
80 CitationsSource
#1Christopher J Black (University of Leeds)H-Index: 13
#2Yan Yiannakou (County Durham and Darlington NHS Foundation Trust)H-Index: 13
Last. Alexander C. Ford (University of Leeds)H-Index: 86
view all 4 authors...
Objectives Few studies have examined the effects of applying the Rome IV criteria for irritable bowel syndrome (IBS) vs the previous standard, the Rome III criteria. We conducted a cross-sectional survey of individuals who self-identify as having IBS to examine this issue. Methods We collected complete demographic, symptom, mood, and psychological health data from 1375 adults who self-identified as having IBS, but were not recruited from a referral population. We applied the Rome III and the Rom...
29 CitationsSource
#1Christopher J Black (University of Leeds)H-Index: 13
#2Yuhong Yuan (McMaster University)H-Index: 35
Last. Alexander C. Ford (University of Leeds)H-Index: 86
view all 7 authors...
Summary Background Although novel therapies for irritable bowel syndrome (IBS) continue to be developed, many doctors rely on more established, traditional therapies as first-line or second-line treatment options. These therapies include soluble fibre (eg, ispaghula husk), antispasmodic drugs, peppermint oil, and gut–brain neuromodulators (including tricyclic antidepressants, selective serotonin reuptake inhibitors, or α-2-δ calcium channel subunit ligands). However, the relative efficacy of tra...
32 CitationsSource
#1Brjánn Ljótsson (KI: Karolinska Institutet)H-Index: 55
#2Michael Jones (Macquarie University)H-Index: 137
Last. Anna Andreasson (KI: Karolinska Institutet)H-Index: 28
view all 6 authors...
BackgroundThe Gastrointestinal Symptom Rating Scale–Irritable Bowel Syndrome (GSRS-IBS) is a 13-item measure of IBS symptom severity. The scale has been used in several studies, but its psychometri...
10 CitationsSource
#1Christopher J Black (University of Leeds)H-Index: 13
#2Nicholas E Burr (University of Leeds)H-Index: 14
Last. Alexander C. Ford (University of Leeds)H-Index: 86
view all 8 authors...
Objective Over half of patients with IBS have either diarrhoea (IBS-D) or a mixed stool pattern (IBS-M). The relative efficacy of licenced pharmacological therapies is unclear in the absence of head-to-head trials. We conducted a network meta-analysis to resolve this uncertainty. Design We searched MEDLINE, Embase, Embase Classic, the Cochrane central register of controlled trials, and Clinicaltrials.gov through January 2019 to identify randomised controlled trials (RCTs) assessing the efficacy ...
49 CitationsSource
4 CitationsSource
Cited By43
Newest
Last. Douglas R. Morgan (UAB: University of Alabama at Birmingham)H-Index: 3
view all 9 authors...
The literature is limited regarding the prevalence of functional gastrointestinal disorders (FGIDs) in Central America, and the role of dietary factors. The Rome IV diagnostic questionnaire and National Cancer Institute Diet History questionnaire were administered in one-on-one interviews to a distributed cross section of the general adult population of Western Honduras. Our aim was to estimate prevalence of common FGIDs and symptoms and their relationships to dietary habits. In total, 815 subje...
2 CitationsSource
#1Riccardo Vasapolli (LMU: Ludwig Maximilian University of Munich)
#1Riccardo Vasapolli (Otto-von-Guericke University Magdeburg)H-Index: 7
Last. Peter Malfertheiner (Otto-von-Guericke University Magdeburg)H-Index: 107
view all 10 authors...
Background null Distinct fecal microbiota profiles are reported to be associated with various subtypes of IBS. Circulating antibodies to cytolethal-distending-toxin B (CdtB) and vinculin are proposed as biomarkers to identify post-infectious IBS. The aim of our study was to analyze serum levels of anti-CdtB and anti-vinculin antibodies in patients with different Functional Gastrointestinal Disorders (FGID) and their correlation with the composition of fecal microbiome. null Methods null The stud...
Source
#1Christopher J Black (University of Leeds)H-Index: 13
#2Heidi M Staudacher (Deakin University)H-Index: 20
Last. Alexander C. Ford (University of Leeds)H-Index: 86
view all 3 authors...
Objective null A diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP) is recommended for irritable bowel syndrome (IBS), if general lifestyle and dietary advice fails. However, although the impact of a low FODMAP diet on individual IBS symptoms has been examined in some randomised controlled trials (RCTs), there has been no recent systematic assessment, and individual trials have studied numerous alternative or control interventions, meaning the best com...
Source
#1Jun-Jie Hou (Tianjin Medical University General Hospital)
#2Xin Wang (Tianjin Medical University General Hospital)H-Index: 1
Last. Bangmao Wang (Tianjin Medical University General Hospital)H-Index: 21
view all 6 authors...
Abstract Irritable bowel syndrome (IBS) is a common functional gastrointestinal disease that affects 3.8–9.2% of the world population. It affects the physiology and psychology of patients and increases the burden on families, the healthcare system, society, and economic development. Presently, a large number of studies have shown that compared to healthy individuals, the composition and diversity of gut microbiota in IBS patients have changed, and the proteolytic activity (PA) in fecal supernata...
Source
#1Brigida Barberio (UNIPD: University of Padua)H-Index: 7
#2Ciaran Judge (St James's University Hospital)H-Index: 1
Last. Alexander C. Ford (University of Leeds)H-Index: 86
view all 4 authors...
Summary null Background null Functional constipation is a common functional bowel disorder in the community, which has a varying prevalence across cross-sectional surveys. We did a contemporaneous systematic review and meta-analysis of studies using comparable methodology and all iterations of the Rome criteria to estimate the global prevalence of functional constipation. null Methods null In this systematic review and meta-analysis, we searched MEDLINE, Embase, and Embase Classic from Jan 1, 19...
1 CitationsSource
#1Umair Akbani (University of Manchester)
#2Dipesh H. Vasant (University of Manchester)H-Index: 10
Source
#1Jongsung Hahn (Yonsei University)
#2Jeongwon Choi (Yonsei University)
Last. Min Jung Chang (Yonsei University)
view all 3 authors...
We conducted a meta-analysis exploring the effect of a low fermentable oligo-, di-, monosaccharides, and polyols diet (LFD) on the overall symptoms, quality of life, and stool habits of irritable bowel syndrome (IBS) patients. The meta-analysis was performed using a random-effects method. The effect size was presented as weighted standardized mean difference (SMD) and 95% confidence interval (CI). Subgroup analyses were conducted to determine the potential effects of covariates on the outcome. T...
Source
#1Kaveh Naseri (Shahid Beheshti University of Medical Sciences and Health Services)
#2Hossein Dabiri (Shahid Beheshti University of Medical Sciences and Health Services)H-Index: 23
Last. Paola Iovino (UNISA: University of Salerno)H-Index: 29
view all 11 authors...
BACKGROUND AND OBJECTIVE Recently, dietary restriction of fermentable carbohydrates (a low-FODMAP diet) in combination with a gluten-free diet (GFD) has been proposed to reduce the symptoms in irritable bowel syndrome (IBS) patients. Different studies reported that IBS has been associated with dysbiosis in the gut microbiota. Additionally, a few studies have reported inflammation in the gastrointestinal (GI) system of adults with IBS. In this study, we aimed to investigate the effects of low FOD...
Source
Irritable bowel syndrome is one of the most common functional bowel disorders, and has a substantial impact on patients' daily lives, as well as a big economic impact on society. It is characterised by abdominal pain, bloating and abdominal distention and altered bowel movements, with a predominance of diarrhoea, constipation, or alternation of these signs, which cannot be explained by a structural or biochemical abnormality. Its aetiopathogenesis and pathophysiological mechanism are unknown. Th...
Source
#1Alfred D. Nelson (Mayo Clinic)H-Index: 10
#2Christopher J Black (St James's University Hospital)H-Index: 13
Last. Alexander C. Ford (University of Leeds)H-Index: 86
view all 6 authors...
BACKGROUND Although bloating is a highly prevalent and troublesome symptom in irritable bowel syndrome with constipation (IBS-C), treatment is empirical with no specific guidelines for its management. AIM To conduct a pairwise and network meta-analysis, using a frequentist approach, of Food and Drug Administration-licensed drugs for IBS-C comparing their efficacy for abdominal bloating as a specific endpoint. METHODS We searched the medical literature through December 2020 to identify randomised...
2 CitationsSource